Search Results

system imposed an undue regulatory and administrative burden on investigators and had arbitrary entry criteria that restricted enrollment. 1 , 2 The COVID-19 pandemic has disrupted all aspects of social, work, and economic life throughout the world. 3 , 4

The COVID-19 pandemic broadly curtailed access to cancer care and highlighted the need to meet patients “where they are,” which included remote access provisions. This need triggered multiple policy changes in 2020 that have accelerated adoption

, rapidly evolving COVID-19 pandemic, which has caused major disruptions in almost all economic sectors, including the food supply chain. Our results showed that lack of paid sick leave was especially common among cancer survivors working in industries

2021: a period capturing healthcare before the COVID-19 pandemic, the pre-vaccination phase, and the post-vaccination phase. Methods: Claims for lung cancer treatment made between 2019 and 2021 were extracted from the database of a national healthcare

number of patients screened in the two cohorts from TriNetX. This difference is likely due to an increase in the number of HCOs contributing data as time passed and COVID-19 pandemic effects on healthcare utilization. This study found no significant

biases in care, and taking on social determinants of health. Of course, all of these conversations are happening in the shadow of the COVID-19 pandemic, which has exposed systemic problems and radically changed care delivery.” The COVID-19 pandemic and

to worsening of their medical condition. Due to the COVID-19 pandemic, the trial was closed for the eight months but is now open to accrual. Conclusions : This trial is currently open and accruing patients. Feasibility will be analyzed after

COVID 19 pandemic; (2) identify the most common respiratory viral pathogens; (3) explore current management approaches and prescriber satisfaction; and (4) explore unmet need and future therapies. Methods: This prospective medical questionnaire was

exploring alternate dosing schedules. The COVID-19 pandemic created a need to cut down on patient visits, thus allowing incorporation of extended dosing (ED) of durvalumab (20mg/kg IV every 4 weeks) into clinical practice. The current study evaluates real

Background: The COVID-19 pandemic has led to the rapid expansion of telehealth use. Telehealth has the potential to improve access for underserved populations who live far distances from well-equipped medical centers. This healthcare modality will